Spruce biosciences reports full year 2023 financial results and provides corporate updates

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended december 31, 2023 and provided corporate updates. “we are grateful to all the patients, families, study team and investigators who supported the cahmelia-203 clinical trial,” said javier szwarcberg.
SPRB Ratings Summary
SPRB Quant Ranking